OP0098 Remission and maintenance of efficacy in a phase 2b study of vobarilizumab, an anti-interleukin 6 receptor nanobody, in patients with moderate-to-severe rheumatoid arthritis despite treatment with methotrexate

Autor: Michael E. Weinblatt, Rieke Alten, Thomas Dörner, K Van Beneden, R.K. Zeldin, P Schoen, EJ Dombrecht, K De Beuf, Patrick Durez

Publikováno v: Oral Presentations.

Background Vobarilizumab is a Nanobody® consisting of an anti-IL-6R domain and an anti-human serum albumin domain in development for treatment of RA. The efficacy and safety were assessed in a 24-week double-blind global phase 2b study in patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::effe47ec63a78cc3250ce6826c3c3003
https://doi.org/10.1136/annrheumdis-2017-eular.3732

Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura

Autor: Marie Scully, J. A. Kremer Hovinga, Spero R. Cataland, Filip Callewaert, K De Beuf, H. De Winter, Flora Peyvandi, R.K. Zeldin, Paul Knöbl

Publikováno v: Peyvandi, F; Scully, M; Kremer Hovinga, Johanna Anna; Knöbl, P; Cataland, S; De Beuf, K; Callewaert, F; De Winter, H; Zeldin, R K (2017). Caplacizumab reduces the frequency of major thromboembolic events, exacerbations, and death in patients with acquired thrombotic thrombocytopenic purpura. Journal of thrombosis and haemostasis, 15(7), pp. 1448-1452. Wiley-Blackwell 10.1111/jth.13716

BACKGROUND Acquired thrombotic thrombocytopenic purpura (aTTP) is a life-threatening autoimmune thrombotic microangiopathy. In spite of treatment with plasma exchange and immunosuppression, patients remain at risk for thrombotic complications, exacer

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::773a5b822e5c823f947382ab26c5bac0
https://pubmed.ncbi.nlm.nih.gov/28445600

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.